logo

Accurate diagnosis and prognosis of Alzheimer’s disease in primary care

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Project
Ended

The overall objective of ADetect is to improve early diagnostics and prognostics of Alzheimer's disease in primary care by utilising novel plasma biomarkers and digital cognitive tests. Misdiagnosis of AD can reach >50% in primary care, which has important consequences both at the personal and societal level. Misdiagnosis, however, can be reduced by measuring AD-related pathology. The novel plasma

Status
Closed
Location
Sweden
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Accurate diagnosis and prognosis of Alzheimer’s disease in primary care

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Accurate diagnosis and prognosis of Alzheimer’s disease in primary care” is an infrastructure initiative, located in Sweden. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

The overall objective of ADetect is to improve early diagnostics and prognostics of Alzheimer's disease in primary care by utilising novel plasma biomarkers and digital cognitive tests. Misdiagnosis of AD can reach >50% in primary care, which has important consequences both at the personal and societal level. Misdiagnosis, however, can be reduced by measuring AD-related pathology. The novel plasma biomarkers may be a cost-effective alternative given their low invasiveness and costs. However, they have not been validated in primary care yet, where much more diverse groups of people are managed. Further, the addition of brief cognitive digital tests that do not require involvement of a specialist may further improve the diagnostic accuracy. Based on the most cost-effective biomarkers, collected in unique prospective study performed in primary care, we will develop algorithms for diagnosis and prognosis of AD in a diverse population, and share them in the form of open and freely available apps. The algorithms will be validated against current standard of truth biomarkers and enhanced to give personalized risk assessments based on patient’s characteristics. Finally, we will investigate whether prospective use of these algorithms will improve treatment, management and care of patients. The development of easy-to-use tools, built on novel cognitive tests and plasma biomarkers, has huge potential to increase the diagnostic accuracy in primary care. A more accurate and timely diagnosis will lead to earlier initiation of currently available AD treatments. Further, when disease-modifying treatments become globally available, there will be an immense pressure on the healthcare system to identify eligible patients. Given the high prevalence of AD, its identification will primarily take place in primary care. With the easy-available proposed biomarkers, we have a great opportunity to develop the necessary tools for primary care to undertake this important task

Location

Country

Sweden

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Article published date

2025-12-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project